Royal Philips has initiated the RADIQAL (Radiation Dose and Image Quality Trial) study, a significant innovation in interventional cardiology aimed at validating the performance of its new ultra-low X-ray dose technology. Integrated into the Philips Azurion image-guided therapy system, this technology is designed to reduce radiation exposure by up to 50% compared to current ClarityIQ settings. The trial, involving 824 coronary artery disease (CAD) patients across Spain, the Czech Republic, and the United States, will generate real-world clinical evidence on whether this innovation can maintain high-quality imaging while significantly lowering radiation for both patients and medical staff.

The importance of this study lies in its potential to address longstanding challenges in image-guided coronary interventions. Percutaneous coronary intervention (PCI), commonly used to treat CAD, relies on fluoroscopic imaging that exposes patients and healthcare providers to ionizing radiation. Reducing radiation without sacrificing image quality is critical, particularly for high-risk patients or those requiring repeat procedures. RADIQAL not only aims to optimize procedural safety and efficiency, but also supports ongoing efforts in minimizing long-term radiation-related risks in cardiology practice.

If successful, the RADIQAL study could set a new standard in interventional cardiology by validating a technology that enhances clinical safety while maintaining diagnostic precision. The outcomes may influence future procedural guidelines, strengthen Philips’ leadership in the imaging domain, and promote widespread adoption of ultra-low dose imaging protocols globally. By combining technological innovation with rigorous clinical validation, Philips reinforces its commitment to advancing precision health and protecting both patients and healthcare providers.

MedTech Spectrum's Summary

Innovative Low-Dose Technology: Philips' new ultra-low X-ray dose protocol, integrated into the Azurion system, reduces radiation exposure by up to 50% compared to existing ClarityIQ settings—without compromising image quality.

Clinical Validation through RADIQAL: The multicenter RADIQAL trial, enrolling 824 CAD patients across Europe and the U.S., is designed to generate real-world evidence on safety, image performance, and procedural efficiency of the new technology.

Potential Global Impact: If proven effective, the innovation could redefine standards in interventional cardiology by minimizing radiation risks for patients and clinicians, promoting safer and more sustainable cardiac care practices.